Literature DB >> 24977625

Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension.

François Potus1, Simon Malenfant, Colin Graydon, Vincent Mainguy, Ève Tremblay, Sandra Breuils-Bonnet, Fernanda Ribeiro, Alexandra Porlier, François Maltais, Sébastien Bonnet, Steeve Provencher.   

Abstract

RATIONALE: Pulmonary arterial hypertension (PAH) is characterized by significant exercise intolerance, which is multifactorial and involves skeletal muscle alterations. There is growing evidence that microRNAs (miRs) are involved in PAH pathogenesis.
OBJECTIVES: We hypothesized that miR-126, an endothelial-specific, proangiogenic miR, is down-regulated in the peripheral muscles of patients with PAH, which would account for skeletal muscle microcirculation loss and exercise intolerance.
MEASUREMENTS AND MAIN RESULTS: Patients with PAH displayed decreases in exercise capacity ([Formula: see text]o2max) and microcirculation loss on quadriceps muscle biopsy (in CD31(+) immunofluorescence experiments) compared to control subjects. Exercise capacity correlated with muscle capillarity (r = 0.84, P < 0.01). At the cellular level, vascular endothelial growth factor (VEGF) and VEGF receptor 2 expression were similar in both groups. Conversely, PAH was associated with a 60% decrease in miR-126 expression in a quantitative reverse transcriptase polymerase chain reaction experiment (P < 0.01), resulting in up-regulation of its targeted protein, Sprouty-related, EVH1 domain-containing protein 1 (SPRED-1), and a marked decrease in the downstream effectors of the VEGF pathway, p-Raf/Raf and p-ERK/ERK, as determined by immunoblot analysis. Using freshly isolated CD31(+) cells from human quadriceps biopsies, we found that the down-regulation of miR-126 in PAH triggered the activation of SPRED-1, impairing the angiogenic response (Matrigel assay). These abnormalities were reversed by treating the PAH cells with miR-126 mimic, whereas inhibition of miR-126 (antagomir) in healthy CD31(+) cells fully mimicked the PAH phenotype. Finally, miR-126 down-regulation in skeletal muscle of healthy rats decreased muscle capillarity in immunofluorescence assays (P < 0.05) and exercise tolerance in treadmill tests (P < 0.05), whereas miR-126 up-regulation increased them in monocrotaline PAH rats.
CONCLUSIONS: We demonstrate for the first time that exercise intolerance in PAH is associated with skeletal muscle microcirculation loss and impaired angiogenesis secondary to miR-126 down-regulation.

Entities:  

Keywords:  angiogenesis; exercise intolerance; microRNA; pulmonary hypertension

Mesh:

Substances:

Year:  2014        PMID: 24977625     DOI: 10.1164/rccm.201402-0383OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  48 in total

1.  Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Adriano R Tonelli; Mostafa K Ahmed; Laith Alkukhun; Frank Cikach; Kulwant Aulak; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2015-10-15       Impact factor: 21.405

Review 2.  Update in Pulmonary Vascular Diseases 2014.

Authors:  Elena A Goncharova; Mark T Gladwin; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

Review 3.  Mechanisms and therapeutic potential of microRNAs in hypertension.

Authors:  Lijun Shi; Jingwen Liao; Bailin Liu; Fanxing Zeng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-05-21       Impact factor: 7.851

4.  Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension.

Authors:  Simon Malenfant; François Potus; Frédéric Fournier; Sandra Breuils-Bonnet; Aude Pflieger; Sylvie Bourassa; Ève Tremblay; Benjamin Nehmé; Arnaud Droit; Sébastien Bonnet; Steeve Provencher
Journal:  J Mol Med (Berl)       Date:  2014-12-30       Impact factor: 4.599

5.  Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Gustavo A Heresi; Steven K Malin; Jarrod W Barnes; Liping Tian; John P Kirwan; Raed A Dweik
Journal:  Ann Am Thorac Soc       Date:  2017-02

6.  Role of miR206 in genistein-induced rescue of pulmonary hypertension in monocrotaline model.

Authors:  Salil Sharma; Soban Umar; Alexander Centala; Mansoureh Eghbali
Journal:  J Appl Physiol (1985)       Date:  2015-10-15

7.  Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.

Authors:  Hyung J Chun; Sébastien Bonnet; Stephen Y Chan
Journal:  Am J Respir Crit Care Med       Date:  2017-01-15       Impact factor: 21.405

Review 8.  Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Authors:  Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

Review 9.  Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Authors:  Jarrod W Barnes; Adriano R Tonelli; Gustavo A Heresi; Jennie E Newman; Noël E Mellor; David E Grove; Raed A Dweik
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

10.  Exercise Training in Diabetes: Start Earlier or Exercise Harder.

Authors:  Haobo Li; Margaret H Hastings; Anthony Rosenzweig
Journal:  Circ Res       Date:  2020-11-05       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.